Skip to main content
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. — Investor Relations & Filings

Ticker · DSGN ISIN · US25056L1035 US Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2022-11-03 Regulatory Filings
Country US United States of America
Listing US DSGN

About Design Therapeutics, Inc.

https://www.designtx.com/

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the three and nine months ended September 30, 2022. The document includes a press release as an exhibit but does not contain the financial results itself, only a notification of their release. The document length is 3568 characters, which is relatively short and consistent with a report announcing results rather than the results themselves. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial data or detailed analysis typical of an Interim/Quarterly Report (IR) or Earnings Release (ER).
2022-11-03 English
SC 13G
Major Shareholding Notification
2022-10-13 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 Results of Operations and Financial Condition and states that the company issued a press release announcing financial results for the quarter ended June 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3556 characters, which is relatively short and consistent with a current report filing announcing an earnings release rather than the earnings release itself. According to the rules, the initial announcement of quarterly financial results (key highlights only) is classified as Earnings Release (ER). However, since this document is a Form 8-K that announces the earnings release and attaches the press release as an exhibit, it is effectively the Earnings Release announcement. The document is not the full transcript or detailed report but the official filing of the earnings announcement. Therefore, the best classification is Earnings Release (ER).
2022-08-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-16 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.